Clinical trials · Illinois
Ulcerative Colitis clinical trials in Illinois
We’re tracking 28 recruiting ulcerative colitis studies with a site in Illinois — including Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07071519RecruitingPhase 3
Risankizumab for young people with ulcerative colitis
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Chicago, IllinoisAges 2–17 - NCT07845487RecruitingPhase 2
Study of PALI-2108 for moderate to severe ulcerative colitis
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Des Plaines, IllinoisAges 18–75 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chicago, IllinoisAges 18–80 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Chicago, IllinoisAges 16–80 - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Belleville, IllinoisAges 18–80 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Chicago, IllinoisAges 18–75 - NCT06636656RecruitingPhase 2
Testing a new drug for ulcerative colitis after other treatments failed
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
Gurnee, IllinoisAges 18–80 - NCT06398626Recruiting
Observational study of etrasimod for ulcerative colitis
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
Chicago, IllinoisAges 18–64 - NCT05287126RecruitingPhase 2
Etrasimod for teens with active ulcerative colitis
This trial tests whether etrasimod can improve ulcerative colitis (UC) symptoms in adolescents with moderate to severe, active disease. It may help reduce inflammation and disease activity, especially if current treatments aren’t working well enough.
Chicago, IllinoisAges 12–17 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Park Ridge, IllinoisAges 2–17 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Chicago, IllinoisAges 18 years+ - NCT06095128RecruitingPhase 4
Combination therapy for ulcerative colitis
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
Chicago, IllinoisAges 18–65 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Des Plaines, IllinoisAges 18–75 - NCT06693310Recruiting
Stopping therapy safely in ulcerative colitis with no inflammation
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
Chicago, IllinoisAges 18–75 - NCT05987852Recruiting
Hyperbaric oxygen therapy for ulcerative colitis flare
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a special chamber) can help people hospitalized with a moderate to severe ulcerative colitis flare get better faster. You will receive the therapy along with standard steroid treatment.
Lake Forest, IllinoisAges 18–85 - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Park Ridge, IllinoisAges 2–17 - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Chicago, IllinoisAges 18–80 - NCT07427017RecruitingPhase 2
Selenium for Ulcerative Colitis Patients on Biologics
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
Chicago, IllinoisAges 18–85 - NCT06405087RecruitingPhase 3
Long-term study of vedolizumab for children with IBD
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Park Ridge, IllinoisAges 2–17 - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Park Ridge, IllinoisAges 2 years+ - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Chicago, IllinoisAges 18–70 - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
Downers Grove, IllinoisAges 18–80 - NCT07686757Enrolling by invitationPhase 4
Study of mirikizumab for ulcerative colitis and Crohn's disease
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Glenview, IllinoisAges 21 years+ - NCT07113522RecruitingPhase 2
Study of new therapies for Crohn's and colitis
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
Glenview, IllinoisAges 18–80
Ulcerative Colitis trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting ulcerative colitis studies listed above.
- GI Alliance - Glenview · 4 studies
- Rush University Medical Center · 4 studies
- Northwestern University · 3 studies
- University of Chicago Medical Center · 3 studies
- Southwest Gastroenterology · 2 studies
- Advocate Children's Hospital
- Advocate Children's Hospital - Park Ridge
- Advocate Children's Hospital - Park Ridge - PIN
What taking part in a ulcerative colitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Ulcerative Colitis trials in other states
Common questions
- Are there ulcerative colitis clinical trials in Illinois?
- Yes. We're currently tracking 28 recruiting ulcerative colitis studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ulcerative colitis study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ulcerative colitis studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.